Customization: | Available |
---|---|
CAS No.: | 1702967-37-0 |
Formula: | C49h71n9o16 |
Still deciding? Get samples of US$ 800/mg
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product name | PSMA-617 |
CAS No. | 1702967-37-0 |
MF | C49H71N9O16 |
MW | 1042.14 |
Melting point | N/A |
Boiling point | 1371.9±65.0 °C(Predicted) |
Density | 1.322±0.06 g/cm3(Predicted) |
Storage | N/A |
Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-emitting Lutetium has already been investigated in several early phase dosimetry studies, demonstrated promising results in phase-2, and recently the first phase-3 trial finished recruitment. In contrast, PSMA-targeting alpha-particle therapy (TAT) has only been evaluated in few preclinical experiments, preliminary dosimetry attempts and some retrospective observational studies, yet.
Our Product purity and quality is guaranteed by lab test for each batch